Characteristics of AEs reports.

Characteristics of AEs reports.

<div><p>Background</p><p>Drug-induced acute respiratory distress syndrome (ARDS) represents a severe adverse drug reaction with substantial implications for patient safety. The pathophysiology of ARDS is characterized by inflammatory cascades, endothelial dysfunction, and inc...

Shranjeno v:

Bibliografske podrobnosti
Glavni avtor:	Jun Hua Lai (22676523) (author)
Drugi avtorji:	Yi Ping Pan (22676526) (author), Zhi Hui Yu (22676529) (author), Wen Fang Jang (22676532) (author), Jun Tao Hu (22676535) (author), Zhan Hong Tang (22676538) (author)
Izdano:	2025
Teme:	Cell Biology Pharmacology Biotechnology Science Policy Mental Health Infectious Diseases reporting odds ratio increased vascular permeability elucidating risk factors compromised gas exchange 86 %), followed study analyzed data identify ade signals prr ), chi drug nomenclature using reported ards population patients requiring hospitalization onset analysis demonstrated induced adverse events enhance patient safety ades occurred within term outcomes associated median onset time first 30 days xlink "> drug xlink "> patient safety study highlights severe outcomes median age induced ards first quarter adverse event ade management ic ), ebgm ), drug dictionaries drug administration united states underlying mechanisms timely intervention targeted ades substantial implications significant morbidity reports originated regulatory activities pulmonary edema prior studies medical dictionary information component inflammatory cascades future research fourth quarter findings revealed endothelial dysfunction disproportionality analyses
Oznake:	Označite Brez oznak, prvi označite!

Podobne knjige/članki

Time-to-onset analysis using the Weibull distribution test.
od: Jun Hua Lai (22676523)
Izdano: (2025)

Signal strength of ADE at the drug level ranked by reports.
od: Jun Hua Lai (22676523)
Izdano: (2025)

The principles of disproportionate measurement and the criteria for signal detection.
od: Jun Hua Lai (22676523)
Izdano: (2025)

Two-by-two contingency table for disproportionality analysis.
od: Jun Hua Lai (22676523)
Izdano: (2025)

Gender Difference analysis of the top 50 drugs ranked by frequency by four methods (ROR PRR IC MGPS).
od: Jun Hua Lai (22676523)
Izdano: (2025)

Outcomes distribution of drug patients with the top 50 positive signal frequency by 4 methods (ROR PRR IC MGPS).
od: Jun Hua Lai (22676523)
Izdano: (2025)

Top 50 drugs sorted by frequency of positive signals stratified by reporter – by 4 methods (ROR PRR IC MGPS).
od: Jun Hua Lai (22676523)
Izdano: (2025)

The top 25 drugs sorted by frequency of positive signals stratified by age – by 4 methods (ROR PRR IC MGPS).
od: Jun Hua Lai (22676523)
Izdano: (2025)

The top 50 drugs by frequency of positive signals stratified by sex – by 4 methods (ROR PRR IC MGPS).
od: Jun Hua Lai (22676523)
Izdano: (2025)

Top 50 Drugs with positive signals by frequency – by four methods (ROR PRR IC MGPS).
od: Jun Hua Lai (22676523)
Izdano: (2025)

Flowchart.
od: Jun Hua Lai (22676523)
Izdano: (2025)

Table 3_Disproportionality analysis of biliary adverse events associated with fibrates using the JADER and FAERS databases.xlsx
od: Satoko Watanabe (59124)
Izdano: (2025)

Data Sheet 1_Disproportionality analysis of biliary adverse events associated with fibrates using the JADER and FAERS databases.pdf
od: Satoko Watanabe (59124)
Izdano: (2025)

Table 2_Disproportionality analysis of biliary adverse events associated with fibrates using the JADER and FAERS databases.xlsx
od: Satoko Watanabe (59124)
Izdano: (2025)

Table 4_Disproportionality analysis of biliary adverse events associated with fibrates using the JADER and FAERS databases.xlsx
od: Satoko Watanabe (59124)
Izdano: (2025)

Table 1_Disproportionality analysis of biliary adverse events associated with fibrates using the JADER and FAERS databases.xlsx
od: Satoko Watanabe (59124)
Izdano: (2025)

Supplementary file 1_Knowledge, attitudes, and practices toward linezolid–serotonergic drug interactions: a cross-sectional study.docx
od: Atheer Aldairem (18834485)
Izdano: (2025)

Sociodemographic data and main univariable subgroup analyses. Other ethnicities includes all ethnicities not categorised as black, mixed, south Asian or white.
od: Alex Gough (16734033)
Izdano: (2025)

Variables extracted from database.
od: Alex Gough (16734033)
Izdano: (2025)

Probability of second result being 10 mg/L different than first result.
od: Alex Gough (16734033)
Izdano: (2025)

Coefficient of variation by patient median CRP (mg/L) with 95% confidence intervals.
od: Alex Gough (16734033)
Izdano: (2025)

Heat map showing the coefficient of variation for multivariable analysis according to median CRP result, sex, age, ethnicity, deprivation and BMI.
od: Alex Gough (16734033)
Izdano: (2025)

Participant selection algorithm.
od: Alex Gough (16734033)
Izdano: (2025)

Table 1_Immune checkpoint inhibitor therapy in advanced cancer: clinical association of irAEs type, inflammatory markers and efficacy.docx
od: Mengying Qian (2541466)
Izdano: (2025)

Table 1_Evaluation of self-efficacy in Spanish nurse prescribers: are they qualified to safely and effectively prescribe medication and health devices?.docx
od: Francisco Javier Gomis-Jimeno (22686371)
Izdano: (2025)

Data Sheet 1_Adjunctive esketamine in propofol-based sedation for gastrointestinal endoscopy: a systematic review and meta-analysis of randomized trials.docx
od: Jiazheng Qi (22679312)
Izdano: (2025)

Association of a COVID-19 diagnosis with adverse events, SCRI design, marketscan and medicare, follow-up starting on the day after time 0.
od: Shelby S. Fisher (22676406)
Izdano: (2025)

Association of a COVID-19 diagnosis with adverse events, cohort design, follow-up starting on the day after time 0.
od: Shelby S. Fisher (22676406)
Izdano: (2025)

Characteristics of included individuals for SCRI and cohort analyses.
od: Shelby S. Fisher (22676406)
Izdano: (2025)

Analysis set for each outcome and definition.
od: Shelby S. Fisher (22676406)
Izdano: (2025)

Estimated Association of a COVID-19 Diagnosis With Neurologic or Immune-Mediated Outcomes: Analysis Starting Follow-Up on the Day After Time 0.
od: Shelby S. Fisher (22676406)
Izdano: (2025)

Eligibility Assessment, Covariate Assessment, Risk Windows, and Reference Windows Relative to Time 0 for the Self-Controlled Risk Interval Design.
od: Shelby S. Fisher (22676406)
Izdano: (2025)

Eligibility assessment, covariate assessment, and follow-up windows relative to time 0 for the cohort design.
od: Shelby S. Fisher (22676406)
Izdano: (2025)

Recommendations for future research for primary care.
od: Zoe Edwards (3823528)
Izdano: (2025)

A table showing the clinical participants who were enrolled in a further or higher education course and their research activity and self-declared involvement.
od: Zoe Edwards (3823528)
Izdano: (2025)

Results of the primary care survey.
od: Zoe Edwards (3823528)
Izdano: (2025)

Achart showing clinician’s self-declared research involvement where 1 is the least and 6 is the greatest.
od: Zoe Edwards (3823528)
Izdano: (2025)

A chart showing the barriers to research ranked as high, medium and low importance by general practice staff.
od: Zoe Edwards (3823528)
Izdano: (2025)

A chart showing the facilitators to research ranked as high, medium and low importance by general practice staff.
od: Zoe Edwards (3823528)
Izdano: (2025)

SPIRIT schedule of enrollment, interventions, and assessment.
od: Kim Christin Honselmann (21176936)
Izdano: (2025)

Cannot write session to /tmp/vufind_sessions/sess_318n05mmgeltlm3lfrk9g1nvfm